SWS Partners Has $3.69 Million Stake in DexCom, Inc. $DXCM

SWS Partners raised its position in DexCom, Inc. (NASDAQ:DXCM) by 45.8% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 55,560 shares of the medical device company’s stock after acquiring an additional 17,458 shares during the quarter. SWS Partners’ holdings in DexCom were worth $3,688,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently modified their holdings of the company. Twin Peaks Wealth Advisors LLC acquired a new position in shares of DexCom during the 2nd quarter worth about $26,000. SJS Investment Consulting Inc. lifted its stake in DexCom by 4,800.0% in the 3rd quarter. SJS Investment Consulting Inc. now owns 392 shares of the medical device company’s stock valued at $26,000 after purchasing an additional 384 shares during the last quarter. Financial Consulate Inc. bought a new position in DexCom during the third quarter worth about $29,000. CVA Family Office LLC grew its holdings in DexCom by 48.5% during the fourth quarter. CVA Family Office LLC now owns 450 shares of the medical device company’s stock worth $30,000 after purchasing an additional 147 shares during the period. Finally, ORG Partners LLC increased its position in DexCom by 124.3% during the fourth quarter. ORG Partners LLC now owns 507 shares of the medical device company’s stock worth $34,000 after buying an additional 281 shares during the last quarter. Institutional investors own 97.75% of the company’s stock.

DexCom Trading Down 0.7%

Shares of NASDAQ:DXCM opened at $62.37 on Thursday. DexCom, Inc. has a 12-month low of $54.11 and a 12-month high of $89.98. The business has a 50 day moving average of $69.56 and a 200-day moving average of $67.34. The company has a quick ratio of 1.59, a current ratio of 1.88 and a debt-to-equity ratio of 0.45. The stock has a market cap of $24.00 billion, a PE ratio of 29.70, a P/E/G ratio of 1.22 and a beta of 1.55.

DexCom (NASDAQ:DXCM) last announced its earnings results on Thursday, February 12th. The medical device company reported $0.68 earnings per share for the quarter, topping analysts’ consensus estimates of $0.65 by $0.03. The company had revenue of $1.26 billion for the quarter, compared to analyst estimates of $1.25 billion. DexCom had a return on equity of 32.12% and a net margin of 17.94%.The firm’s quarterly revenue was up 13.1% compared to the same quarter last year. During the same quarter last year, the company earned $0.45 earnings per share. As a group, equities research analysts forecast that DexCom, Inc. will post 2.03 earnings per share for the current year.

Insiders Place Their Bets

In other news, EVP Michael Jon Brown sold 1,700 shares of DexCom stock in a transaction on Monday, March 16th. The stock was sold at an average price of $64.85, for a total transaction of $110,245.00. Following the completion of the sale, the executive vice president owned 112,904 shares of the company’s stock, valued at approximately $7,321,824.40. This trade represents a 1.48% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.32% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several research firms have issued reports on DXCM. Robert W. Baird set a $87.00 price objective on DexCom in a research note on Friday, February 13th. Sanford C. Bernstein reissued an “outperform” rating and set a $86.00 target price (up from $84.00) on shares of DexCom in a report on Friday, January 9th. Weiss Ratings upgraded DexCom from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Wednesday, March 4th. Citigroup raised their price target on DexCom from $77.00 to $84.00 and gave the company a “buy” rating in a report on Wednesday, March 11th. Finally, Leerink Partners reaffirmed an “outperform” rating and set a $92.00 price objective on shares of DexCom in a research report on Tuesday, December 16th. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $86.50.

DexCom Company Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.